Oppenheimer Downgrades Myriad Genetics (MYGN) to Perform
More News related to MYGN
- Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Myriad Genetics (MYGN) Misses Q1 EPS by 3c
- Myriad Genetics Reports First Quarter Fiscal 2010 Financial Results
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
Oppenheimer downgrades Myriad Genetics (Nasdaq: MYGN) from Outperform to Perform.
To see more analyst ratings on MYGN Click Here.
Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of molecular diagnostic and therapeutic products.
Related Categories
DowngradesStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
